We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Novo Nordisk's GLP-1 Dominance Fading After Lilly's Clinical Wins?
Read MoreHide Full Article
Key Takeaways
Novo Nordisk stock fell 21% after CagriSema lost to Zepbound in the phase III REDEFINE 4 obesity study.
Lilly's orforglipron beat Rybelsus in ACHIEVE-3, cutting A1C by 2.2% and weight by 9.2% at 52 weeks.
Novo Nordisk plans to cut U.S. list prices of Wegovy, Ozempic and Rybelsus to $675 monthly by 2027.
Novo Nordisk (NVO - Free Report) has endured a brutal week, with its shares plunging 21% after a series of disappointing clinical results and mounting pricing pressures erased virtually all the gains accumulated since the 2021 approval of its blockbuster obesity therapy, Wegovy (semaglutide).
Eli Lilly (LLY - Free Report) has emerged as Novo Nordisk’s most formidable rival in the GLP-1 market for obesity. Its Zepbound (tirzepatide injection) competes directly with NVO’s Wegovy and, despite launching later, has steadily eroded Wegovy’s market share, driven largely by data showing superior weight-loss efficacy.
Last week, Novo Nordisk announced that Eli Lilly’s Zepbound 15 mg outperformed its lead next-generation obesity treatment candidate, CagriSema (cagrilintide 2.4 mg/semaglutide 2.4 mg) in the 84-week, phase III REDEFINE 4 study. Among patients who adhered to treatment, Zepbound delivered 25.5% weight loss at 84 weeks compared to 23% with CagriSema. As a result, CagriSema failed to meet the primary endpoint of demonstrating non-inferiority to tirzepatide, marking a clear competitive win for Lilly’s therapy.
The efficacy gap reinforced Zepbound’s positioning as the more potent weight-loss option over CagriSema at the studied doses. The outcome is a setback for Novo Nordisk’s effort to counter Lilly’s momentum in the obesity market, particularly as Zepbound continues to set the benchmark for efficacy. NVO has submitted CagriSema to the FDA based on earlier studies and plans additional studies, including higher-dose combinations. Still, for now, Zepbound has strengthened its leadership in head-to-head performance. This was detrimental to the stock.
Adding to the turmoil, later the same week, Eli Lilly reported that its oral GLP-1 candidate, orforglipron, outperformed Novo Nordisk’s Rybelsus (oral semaglutide) in the head-to-head phase III ACHIEVE-3 study in type II diabetes (T2D). At 52 weeks, the highest dose of orforglipron (36 mg) reduced A1C by 2.2% compared to 1.4% with Rybelsus 14 mg, while also delivering 9.2% weight loss (19.7 lbs) compared to 5.3% (11.0 lbs) with Rybelsus 14 mg — a 73.6% greater relative weight reduction. Orforglipron met superiority criteria across the primary and all key secondary endpoints, including significantly higher proportions of patients achieving stringent A1C targets.
Beyond glycemic control and weight loss, orforglipron demonstrated favorable effects on several cardiovascular risk markers and offers the added convenience of no food or water timing restrictions — a potential practical edge over Rybelsus. The overall data position orforglipron as a potentially more potent and user-friendly oral GLP-1 option, tightening its competitive grip in the cardiometabolic space.
Further complicating the outlook, Novo Nordisk plans steep U.S. list price cuts for its three largest revenue drivers — Wegovy, Ozempic (semaglutide injection for T2D) and Rybelsus — lowering them to $675 per month from January 2027 to expand patient access. While the move could help remove affordability barriers and broaden uptake, it risks compressing margins across NVO’s core franchise at a time of intensifying competition from Eli Lilly’s rapidly gaining obesity and diabetes portfolio. With these therapies accounting for a substantial share of Novo Nordisk’s revenue base, deeper price reductions could heighten execution risk, forcing the company to rely more heavily on volume growth and market share defense to offset pricing pressure — an increasingly challenging task in a fiercely competitive GLP-1 landscape.
Competition Heating Up in the Obesity Space
Eli Lilly markets its tirzepatide injections as Zepbound for obesity and Mounjaro for T2D. Despite being on the market for just over three years, Mounjaro and Zepbound have seen exceptional sales growth, becoming LLY’s key top-line drivers. In 2025, the drugs generated combined sales of $36.5 billion, comprising around 56% of the company’s total revenues. A regulatory application seeking the FDA approval of Lilly’s much-anticipated oral GLP-1 pill for obesity, orforglipron, is also currently under review, with a decision expected soon.
The obesity space has garnered much of the spotlight over the past year due to the sizeable and still underpenetrated market opportunity. Smaller biotech firms, like Viking Therapeutics (VKTX - Free Report) , are also advancing GLP-1-based therapies to challenge the incumbents. Viking Therapeutics’ dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity. Viking Therapeutics plans to advance oral VK2735 into phase III development for obesity in the third quarter of 2026.
NVO Stock Price, Valuation & Estimates
In the past six months, Novo Nordisk shares have lost 34% against the industry’s 24.5% growth. The company has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
NVO Stock Underperforms the Industry, Sector & the S&P 500
Image Source: Zacks Investment Research
Novo Nordisk is trading at a discount to the industry, as seen in the chart below. Going by the price/earnings ratio, the company’s shares currently trade at 11.17 forward earnings, which is lower than 18.70 for the industry. The stock is trading much below its five-year mean of 29.25.
NVO Stock Valuation
Image Source: Zacks Investment Research
Earnings estimates for 2026 have declined from $3.54 to $3.36 per share over the past 60 days. During the same time frame, Novo Nordisk’s 2027 earnings estimates have declined from $3.65 to $3.30.
NVO Estimate Movement
Image Source: Zacks Investment Research
Novo Nordisk currently carries a Zacks Rank #4 (Sell).
View the Zacks #1 Rank List
Image: Shutterstock
Is Novo Nordisk's GLP-1 Dominance Fading After Lilly's Clinical Wins?
Key Takeaways
Novo Nordisk (NVO - Free Report) has endured a brutal week, with its shares plunging 21% after a series of disappointing clinical results and mounting pricing pressures erased virtually all the gains accumulated since the 2021 approval of its blockbuster obesity therapy, Wegovy (semaglutide).
Eli Lilly (LLY - Free Report) has emerged as Novo Nordisk’s most formidable rival in the GLP-1 market for obesity. Its Zepbound (tirzepatide injection) competes directly with NVO’s Wegovy and, despite launching later, has steadily eroded Wegovy’s market share, driven largely by data showing superior weight-loss efficacy.
Last week, Novo Nordisk announced that Eli Lilly’s Zepbound 15 mg outperformed its lead next-generation obesity treatment candidate, CagriSema (cagrilintide 2.4 mg/semaglutide 2.4 mg) in the 84-week, phase III REDEFINE 4 study. Among patients who adhered to treatment, Zepbound delivered 25.5% weight loss at 84 weeks compared to 23% with CagriSema. As a result, CagriSema failed to meet the primary endpoint of demonstrating non-inferiority to tirzepatide, marking a clear competitive win for Lilly’s therapy.
The efficacy gap reinforced Zepbound’s positioning as the more potent weight-loss option over CagriSema at the studied doses. The outcome is a setback for Novo Nordisk’s effort to counter Lilly’s momentum in the obesity market, particularly as Zepbound continues to set the benchmark for efficacy. NVO has submitted CagriSema to the FDA based on earlier studies and plans additional studies, including higher-dose combinations. Still, for now, Zepbound has strengthened its leadership in head-to-head performance. This was detrimental to the stock.
Adding to the turmoil, later the same week, Eli Lilly reported that its oral GLP-1 candidate, orforglipron, outperformed Novo Nordisk’s Rybelsus (oral semaglutide) in the head-to-head phase III ACHIEVE-3 study in type II diabetes (T2D). At 52 weeks, the highest dose of orforglipron (36 mg) reduced A1C by 2.2% compared to 1.4% with Rybelsus 14 mg, while also delivering 9.2% weight loss (19.7 lbs) compared to 5.3% (11.0 lbs) with Rybelsus 14 mg — a 73.6% greater relative weight reduction. Orforglipron met superiority criteria across the primary and all key secondary endpoints, including significantly higher proportions of patients achieving stringent A1C targets.
Beyond glycemic control and weight loss, orforglipron demonstrated favorable effects on several cardiovascular risk markers and offers the added convenience of no food or water timing restrictions — a potential practical edge over Rybelsus. The overall data position orforglipron as a potentially more potent and user-friendly oral GLP-1 option, tightening its competitive grip in the cardiometabolic space.
Further complicating the outlook, Novo Nordisk plans steep U.S. list price cuts for its three largest revenue drivers — Wegovy, Ozempic (semaglutide injection for T2D) and Rybelsus — lowering them to $675 per month from January 2027 to expand patient access. While the move could help remove affordability barriers and broaden uptake, it risks compressing margins across NVO’s core franchise at a time of intensifying competition from Eli Lilly’s rapidly gaining obesity and diabetes portfolio. With these therapies accounting for a substantial share of Novo Nordisk’s revenue base, deeper price reductions could heighten execution risk, forcing the company to rely more heavily on volume growth and market share defense to offset pricing pressure — an increasingly challenging task in a fiercely competitive GLP-1 landscape.
Competition Heating Up in the Obesity Space
Eli Lilly markets its tirzepatide injections as Zepbound for obesity and Mounjaro for T2D. Despite being on the market for just over three years, Mounjaro and Zepbound have seen exceptional sales growth, becoming LLY’s key top-line drivers. In 2025, the drugs generated combined sales of $36.5 billion, comprising around 56% of the company’s total revenues. A regulatory application seeking the FDA approval of Lilly’s much-anticipated oral GLP-1 pill for obesity, orforglipron, is also currently under review, with a decision expected soon.
The obesity space has garnered much of the spotlight over the past year due to the sizeable and still underpenetrated market opportunity. Smaller biotech firms, like Viking Therapeutics (VKTX - Free Report) , are also advancing GLP-1-based therapies to challenge the incumbents. Viking Therapeutics’ dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity. Viking Therapeutics plans to advance oral VK2735 into phase III development for obesity in the third quarter of 2026.
NVO Stock Price, Valuation & Estimates
In the past six months, Novo Nordisk shares have lost 34% against the industry’s 24.5% growth. The company has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
NVO Stock Underperforms the Industry, Sector & the S&P 500
Novo Nordisk is trading at a discount to the industry, as seen in the chart below. Going by the price/earnings ratio, the company’s shares currently trade at 11.17 forward earnings, which is lower than 18.70 for the industry. The stock is trading much below its five-year mean of 29.25.
NVO Stock Valuation
Earnings estimates for 2026 have declined from $3.54 to $3.36 per share over the past 60 days. During the same time frame, Novo Nordisk’s 2027 earnings estimates have declined from $3.65 to $3.30.
NVO Estimate Movement
Novo Nordisk currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.